Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Period	PE Ratio
2020-12-31	-0.94
2021-12-31	-1.76
2022-12-31	-1.76
2023-12-31	-2.12
2024-12-31	-2.55

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRLD	$4.29	-2.61%	0.34M
3
4
5

Prelude Therapeutics Incorporated (PRLD) PE Ratio

PE Ratio Data

Get Prelude Therapeutics Incorporated Data in Excel

More PRLD Financial Data